S32 is a Sunnyvale, California-based venture capital firm founded in 2017 by Bill Maris, the founder and former CEO of Google Ventures. The firm is named after the atomic number of germanium — a semiconductor element — reflecting its orientation toward deep technology and scientific frontier companies. S32 invests primarily at Series A and B stages across high tech, life sciences, and enterprise applications.

The VC participated in Beacon Biosignals' oversubscribed $86M Series B round in November 2025, alongside GV, Nexus NeuroTech Ventures, Innoviva, Catalio, and Takeda. S32's broader portfolio includes CrowdStrike, Coinbase, Gusto, and life science companies including Aspen Neuroscience (Parkinson's cell therapy). The firm has 103 portfolio companies and 29 team members.

S32 invests primarily in the United States. For neurotech, it is most relevant for companies at Series A/B stage with a strong data, AI, or life science platform angle. It is not a dedicated neurotech specialist but has demonstrated willingness to co-invest in leading brain health companies.